巴西替尼治疗小儿重度斑秃的疗效和安全性：来自实际临床实践的数据。

IF 2.7 3区医学 Q2 DERMATOLOGY

Dermatology Pub Date : 2025-08-07 DOI:10.1159/000547786

Dandan Wei, Dan Huang, Shufen Wang, Wenyu Li, Hongdi Xiong, Sijian Wen

{"title":"巴西替尼治疗小儿重度斑秃的疗效和安全性：来自实际临床实践的数据。","authors":"Dandan Wei, Dan Huang, Shufen Wang, Wenyu Li, Hongdi Xiong, Sijian Wen","doi":"10.1159/000547786","DOIUrl":null,"url":null,"abstract":"Introduction: Alopecia areata (AA) is an autoimmune disorder with a higher prevalence in pediatric patients than adults, but treatment options remain limited. Baricitinib, a Janus kinase (JAK)-1/2 inhibitor, has shown efficacy in adults with severe AA, yet data on its use in pediatric patients are limited.Methods: This study included pediatric patients (ages 2-18) with severe AA (Severity of Alopecia Tool [SALT] ≥50) treated with baricitinib for at least 3 months between January 2023 and October 2024. Demographics, SALT scores before and after treatment, and adverse events were collected.Results: Thirty-three patients were included, with a mean age of 9.93 years and average disease duration of 23.44 months. Sixteen patients received 2 mg and 17 received 4 mg of baricitinib. At baseline, 54.5% had a SALT score above 90. After treatment, 45.5% of patients had a 50% reduction in their SALT score. The average treatment duration was 6.5 months. Adverse events included elevated ALT (n = 1), acne (n = 1), and upper respiratory infection (n = 1), with no serious adverse events.Conclusion: Baricitinib demonstrated clinical efficacy and good tolerance in pediatric patients with severe AA.","PeriodicalId":11185,"journal":{"name":"Dermatology","volume":" ","pages":"1-6"},"PeriodicalIF":2.7000,"publicationDate":"2025-08-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Efficacy and Safety of Baricitinib in the Treatment of Severe Alopecia Areata in Pediatric Patients: Data from Real-Clinical Practice.\",\"authors\":\"Dandan Wei, Dan Huang, Shufen Wang, Wenyu Li, Hongdi Xiong, Sijian Wen\",\"doi\":\"10.1159/000547786\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Introduction: Alopecia areata (AA) is an autoimmune disorder with a higher prevalence in pediatric patients than adults, but treatment options remain limited. Baricitinib, a Janus kinase (JAK)-1/2 inhibitor, has shown efficacy in adults with severe AA, yet data on its use in pediatric patients are limited.Methods: This study included pediatric patients (ages 2-18) with severe AA (Severity of Alopecia Tool [SALT] ≥50) treated with baricitinib for at least 3 months between January 2023 and October 2024. Demographics, SALT scores before and after treatment, and adverse events were collected.Results: Thirty-three patients were included, with a mean age of 9.93 years and average disease duration of 23.44 months. Sixteen patients received 2 mg and 17 received 4 mg of baricitinib. At baseline, 54.5% had a SALT score above 90. After treatment, 45.5% of patients had a 50% reduction in their SALT score. The average treatment duration was 6.5 months. Adverse events included elevated ALT (n = 1), acne (n = 1), and upper respiratory infection (n = 1), with no serious adverse events.Conclusion: Baricitinib demonstrated clinical efficacy and good tolerance in pediatric patients with severe AA.\",\"PeriodicalId\":11185,\"journal\":{\"name\":\"Dermatology\",\"volume\":\" \",\"pages\":\"1-6\"},\"PeriodicalIF\":2.7000,\"publicationDate\":\"2025-08-07\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Dermatology\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1159/000547786\",\"RegionNum\":3,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"DERMATOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Dermatology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1159/000547786","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"DERMATOLOGY","Score":null,"Total":0}

引用次数: 0

摘要

斑秃（AA）是一种自身免疫性疾病，儿童患者的患病率高于成人，但治疗选择仍然有限。Baricitinib是一种Janus激酶(JAK)-1/2抑制剂，已显示对成人严重AA患者有效，但其在儿科患者中的应用数据有限。方法：本研究纳入了2023年1月至2024年10月期间接受巴西替尼治疗至少3个月的重度AA （SALT≥50）患儿（2-18岁）。统计数据、治疗前后的SALT评分和不良事件。结果：纳入33例患者，平均年龄9.93岁，平均病程23.44个月。16例患者接受2mg， 17例接受4mg的巴西替尼。基线时，54.5%的患者SALT评分高于90分。治疗后，45.5%的患者的SALT评分降低了50%。平均治疗时间为6.5个月。不良事件包括ALT升高（n=1）、痤疮（n=1）、上呼吸道感染（n=1），无严重不良事件。结论：Baricitinib对儿童重度AA患者具有良好的临床疗效和耐受性。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

Efficacy and Safety of Baricitinib in the Treatment of Severe Alopecia Areata in Pediatric Patients: Data from Real-Clinical Practice.

Introduction: Alopecia areata (AA) is an autoimmune disorder with a higher prevalence in pediatric patients than adults, but treatment options remain limited. Baricitinib, a Janus kinase (JAK)-1/2 inhibitor, has shown efficacy in adults with severe AA, yet data on its use in pediatric patients are limited.

Methods: This study included pediatric patients (ages 2-18) with severe AA (Severity of Alopecia Tool [SALT] ≥50) treated with baricitinib for at least 3 months between January 2023 and October 2024. Demographics, SALT scores before and after treatment, and adverse events were collected.

Results: Thirty-three patients were included, with a mean age of 9.93 years and average disease duration of 23.44 months. Sixteen patients received 2 mg and 17 received 4 mg of baricitinib. At baseline, 54.5% had a SALT score above 90. After treatment, 45.5% of patients had a 50% reduction in their SALT score. The average treatment duration was 6.5 months. Adverse events included elevated ALT (n = 1), acne (n = 1), and upper respiratory infection (n = 1), with no serious adverse events.

Conclusion: Baricitinib demonstrated clinical efficacy and good tolerance in pediatric patients with severe AA.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Dermatology 医学-皮肤病学

CiteScore

6.40

自引率

2.90%

发文量

审稿时长

1 months

期刊介绍： Published since 1893, ''Dermatology'' provides a worldwide survey of clinical and investigative dermatology. Original papers report clinical and laboratory findings. In order to inform readers of the implications of recent research, editorials and reviews prepared by invited, internationally recognized scientists are regularly featured. In addition to original papers, the journal publishes rapid communications, short communications, and letters to ''Dermatology''. ''Dermatology'' answers the complete information needs of practitioners concerned with progress in research related to skin, clinical dermatology and therapy. The journal enjoys a high scientific reputation with a continually increasing impact factor and an equally high circulation.